NattoPharma Names Vladimir Badmaev Head of R&D, Product Development

May 16, 2012, Oslo, Norway.  The Board of publicly-traded company NattoPharma ASA, announces today that Vladimir Badmaev MD, PhD has accepted the appointment as Head of Research and Development at NattoPharma. Dr. Badmaev will lead NattoPharma’s research and development program to support its premium brand of vitamin K2, MenaQ7®, and also head the development of a line of biotechnology products based on fermentation technologies and a solvent-free green technology to broaden the food, nutraceutical and pharmaceutical applications of NattoPharma products.

“Dr. Badmaev is a much welcome addition to the NattoPharma team,” stated NattoPharma CEO Frode Bohan. “He has pioneered many leading ingredients in the natural products industry in his career, and his proven record of guiding product development will surely help us grow our Vitamin K2 franchise, as well as creating additional product offerings as we expand our biotechnology base.”

Dr. Badmaev received his MD and PhD (Immunopharmacology) in Bialystok, Poland and training in clinical and anatomical pathology at Kings County Hospital and Downstate Medical Center, New York (1982-1985).  He is the author/coauthor of over 70 scientific and popular scientific articles, 13 books, 13 US and International patents and 9 successful IND applications with the FDA, several self-affirmed GRAS documents and NDI applications.

Prior to appointment with NattoPharma Dr. Badmaev has successfully served as a VP and Medical and Scientific Director with Sabinsa Inc. and PLThomas Inc. respectively, assisting those companies in building pre-clinical and clinical research on the innovative standardized food supplements. Recently, in a joint venture with a group of international investors he established American Medical Holdings, Inc., dedicated to developing natural and synthetic pharmaceuticals which he terms “Interactive nutrients.”

Dr. Badmaev is the 2004 recipient of the New Jersey R&D Council Thomas Alva Edison Award for ForsLean®, an ingredient promoting Lean Body Mass. He is the 2005 recipient of the Award for Bioperine® in promoting nutrient bioavailability and the 2009 recipient of Thomas Alva Edison Award for composition of Garcitrin ® natural and synthetic HCA for body weight management. Dr. Badmaev participated in the following Medical/Scientific Societies: International Society of Immunopharmacology (1982), American Association of Clinical Pathologists (1983), American Medical Association (1984), Research and Development Council of New Jersey (1996).

About NattoPharma
NattoPharma, Norway is the exclusive international supplier of MenaQ7, the natural vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.

For more information, please visit www.nattopharma.com

About MenaQ7
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.

For more information on the health benefits of MenaQ7, please visit www.menaq7.com

For more information, please contact:
Bertil Andersson
Chief Operations Officer (COO)
Mobile phone: +47 900 91 910
E-mail: bertil@nattopharma.com

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.